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ERCC1 mRNA Expression Is Not Associated with Response
and Survival after Platinum-Based Chemotherapy
Regimens in Advanced Non-Small Cell Lung Cancer
Richard Booton, PhD, MRCP,* Tim Ward, PhD,* Linda Ashcroft, BSc,* Julie Morris, PhD,†
Jim Heighway, PhD,‡ and Nick Thatcher, PhD, FRCP*†
Background: Platinum-based therapy is pivotal to the treatment of
advanced non-small cell lung Cancer (NSCLC). Excision repair
cross-complementation group 1 (ERCC1) is a key component of the
platinum-DNA repair machinery responsible for nucleotide excision
repair. We sought to determine the influence of ERCC1 mRNA
expression in advanced NSCLC on chemotherapy response, toxicity,
and survival after platinum-based chemotherapy.
Methods: Patients randomized to a phase III trial of platinum-based
chemotherapy were eligible for inclusion. Formalin-fixed paraffin-
embedded tumor biopsies were retrieved for mRNA extraction and
purification before quantitative real-time polymerase chain reaction
analysis using Taqman technology. Expression data were correlated
with treatment response, toxicity, and overall survival.
Results: Sixty-six patients were enrolled. No statistically significant
relationship existed between ERCC1 mRNA expression and re-
sponse to chemotherapy (p  0.794) or hematological toxicity. No
statistically significant difference in median survival was demon-
strated according to ERCC1 expression (high expression, 415 days,
95% confidence interval [95%CI]: 197–633 days; low expression,
327 days [95%CI: 211–433 days]; p 0.801). High ERCC1 mRNA
expression was associated with a hazard ratio for death of 0.96 (95%
CI 0.919–1.004; p  0.08).
Conclusion: In contrast to recent publications, ERCC1 mRNA
expression in our study did not favor a prognostically better outcome
after platinum-based chemotherapy in advanced NSCLC. We ex-
plore potential reasons for this, including the need for cautious
interpretation of mRNA expression data from archival materials and
highlight the need for additional translational research linking gene
expression with a promising ERCC1 polymorphism.
(J Thorac Oncol. 2007;2: 902–906)
Most patients with lung cancer present at a stage at whichcurrent cytotoxic regimens are generally not suffi-
ciently effective to deliver curative treatment; consequently,
this common disease remains the leading cause of cancer-
related death worldwide.1 Platinum-based chemotherapy is a
pivotal treatment in the management of advanced non-small
cell lung cancer (NSCLC),2 but current standard practice only
attains a median survival of approximately 8 months. Plati-
num drugs exert their cytotoxicity by forming platinum-DNA
adducts and, subsequently, intra- and less commonly interstrand
DNA crosslinks to disrupt replication and, if unrepaired, can
result apoptotic cell death.3 A number of resistance mechanisms
may be important in ameliorating cytotoxicity, including alter-
ations in platinum intracellular uptake,4 detoxification via
glutathione conjugation,5 or variation of components of the
nucleotide excision repair (NER) pathway, such as xero-
derma pigmentosum group D (XPD) polymorphisms,6 a re-
pair system important in the removal of cisplatin-DNA in-
trastrand crosslinks. Pivotal to the efficacy of this pathway is
the product of the excision repair cross-complementation
group 1 (ERCC1) gene (DNA excision repair protein ERCC-1),
which seems to be a rate-limiting enzyme for NER.7–9 Its
importance is exemplified by the lack of a known deficiency
state in humans (unlike XPD, for example), with deficiency
most likely being inconsistent with life. Preliminary studies
in numerous cancer cell lines have demonstrated that NER is
important in cisplatin resistance and that ERCC1 mRNA
expression may affect resistance to cisplatin.10–13 Differences
in ERCC1 mRNA expression in gastrointestinal and ovarian
malignancies have been associated with differential survival
after platinum-based chemotherapy.14–17 We investigated the
effect of ERCC1 mRNA expression on response and survival
among patients with advanced NSCLC receiving platinum-
based chemotherapy as part of the BTOG1 trial.18
MATERIALS AND METHODS
Sample Preparation
After written informed consent was given, paraffin-
embedded tumor biopsies were obtained from patients with
advanced NSCLC participating in the BTOG1 trial for the
determination of ERCC1 mRNA expression data. The results
of BTOG1 and the chemotherapy protocol have been de-
scribed previously.18 Briefly, patients with biopsy-proven
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stage III to IV NSCLC not suitable for curative surgery or
radiotherapy were randomized to receive four cycles of either
DCb (docetaxel 75 mg/m2, carboplatin AUC 6), or MIC/
MVP (mitomycin 6 mg/m2, ifosfamide 3 g/m2, cisplatin 50
mg/m2, or mitomycin 6 mg/m2, vinblastine 6 mg/m2, cisplatin
50 mg/m2, respectively), every 3 weeks. Patients from two
centers participating in the BTOG1 trial form the basis of this
report (n  108). Not all samples were available for RNA
extraction or provided amplifiable RNA after preparation.
RNA was extracted from 3  10 m sections from each
block using the Paraffin Block RNA Extraction Kit (Ambion,
Austin, Texas) according to the manufacturer’s instructions
and cleaned using the RNA MinElute Cleanup Kit (Qiagen,
UK). RNA concentration was qualitatively assessed using a
Nanodrop UV spectrophotometer. cDNA was synthesized using




Quantitative gene expression analysis by reverse tran-
scriptase-polymerase chain reaction (RT-PCR) was under-
taken using 3 to 5 l cDNA and the Universal TaqMan PCR
protocol (qPCR) and the ABI 7700 sequence detection sys-
tem using primers for ERCC1 and an internal control gene,
APPBP2, which has previously been shown to be expressed
at equivalent levels in NSCLC and matched normal tissue
(Applied Biosystems Assays on Demand, reference numbers
Hs00157415, Hs00197271 respectively).19,20 The reactions
were performed in triplicate, and cycle thresholds were cal-
culated based on the mean of these three reactions. The
difference in gene expression between ERCC1 and the inter-
nal control was calculated by subtracting the cycle threshold
for ERCC1 from that of the internal control (CT). As cDNA
was derived from paraffin-embedded biopsy samples that
demonstrate variable PCR efficiency (Figure 1), and because
the interpretation of qPCR data relies heavily on the assump-
tion of equivalent PCR efficiency (i.e., two copies made per
cycle of PCR) for both the gene of interest and internal
control, we determined the PCR efficiency of each reaction
using LinReg PCR software and calculated corrected cycle
threshold values based on a PCR efficiency of 2.21 Gene
expression values were then calculated and correlated with
patient demographics, tumor response, and survival. The
South Manchester Research and Ethics Committee granted
ethical approval for this study.
Statistical Analysis
We used 2 tests to evaluate the association of response
with demographic variables and expression of ERCC1
mRNA. Spearman correlations were used to determine the
associations between hematological and non-hematological
chemotherapy-related toxicity. Median survival was evalu-
ated using the log-rank test and Kaplan Meier survival
curves. Hazard ratios for death according to ERCC1 mRNA
expression were also calculated. Statistical significance was
based on a two-sided significance of 0.05.
FIGURE 1. Polymerase chain reaction efficiency in fresh fro-
zen tumor and paraffin-embedded tumor biopsies. A, Real-
time polymerase chain reaction plot of cDNA derived from
three fresh frozen lung cancer tissues for a number of genes.
The differences in the curve gradients in exponential phase
make direct comparison of gene expression data difficult
without prior correction. B, Similar data from cDNA derived
from archival sources. The number of successful reactions is
limited by the archival source, threshold value generally oc-
curs later, and polymerase chain reaction efficiency (curve
gradient) remains problematic.
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RESULTS
Quantitative PCR data were available from 66 of 108
patients (61%) recruited from the BTOG1 trial. Most patients
demonstrated over-expression of ERCC1 relative to the in-
ternal control, but there was no significant relationship be-
tween chemotherapy response and age, sex, stage, or histology.
However, performance status demonstrated a significant rela-
tionship with response to chemotherapy (p  0.013) (Table 1).
No significant relationship was demonstrated between ERCC1
mRNA expression and histology (p  0.552), sex (p  0.428),
stage (p 0.113), or performance status (p 0.628) (Table 2).
ERCC1 mRNA expression was classified as high or low/no
expression according to the median value (CT 9.0) before
relating it to treatment response and survival.
Toxicity and Response to Chemotherapy
Overall, 33% demonstrated an objective response, 29%
stable disease, and 38% progressive disease/cancer death. No
significant relationship existed between ERCC1 mRNA ex-
pression and response to chemotherapy (p  0.794). Objec-
tive response rates were 36%, stable disease 27%, and pro-
gressive disease 36% for high ERCC1 mRNA expression and
28%, 32%, and 40%, respectively, for low ERCC1 expres-
sion. No significant differences were demonstrated for
ERCC1 mRNA expression levels in patients attaining an
objective response, stable disease, or progressive disease
(CT 8.98 vs 9.06 vs 6.44 respectively; ANOVA p  0.44).
ERCC1 mRNA expression was not associated with any grade
of hematological or non-hematological toxicity, with the
exception of a significant negative correlation with rash ( 
0.27; p  0.031).
Survival
There was no significant difference in median survival
between high and low ERCC1 mRNA expression (415 days,
95% confidence interval [95%CI]: 197–633 days and 327
days [95%CI: 211–433 days]; p  0.801) (Figure 2). How-
ever, high ERCC1 mRNA expression was associated with a
hazard ratio for death of 0.96 (95%CI: 0.919–1.004, p 
0.08), which provides some limited evidence that higher
ERCC1 expression may be related to better survival.
DISCUSSION
The central role of NER in platinum sensitivity was first
exemplified by the exquisite sensitivity of teratoma cell lines
to cisplatin that demonstrated an inability to repair platinum-
DNA intrastrand adducts as a consequence of deficient
NER.22 Three studies have recently thrust ERCC1 expression
to the fore in the therapy of NSCLC cancer in adjuvant and
advanced settings.23–25 In the adjuvant setting, Olaussen et al.
recently reported the significant survival advantages for pa-
tients (n  761) receiving adjuvant cisplatin/vinorelbine
chemotherapy and with absent ERCC1 expression deter-
mined by immunohistochemistry (adjusted hazard ratio for
death, 0.65; 95%CI: 0.50-0.86; p  0.002), but there was no
benefit for patients with ERCC1-positive tumors. Interest-
TABLE 1. Relationship of BTOG1 Patient Characteristics
with Treatment Response (n  58)
Variable
Chemotherapy Response
p ValueOR SD PD
Histology 0.244
Squamous 10 6 9
Adenocarcinoma 1 7 8
Large Cell 1 0 0
Undifferentiated 1 0 0
NSCLC- NOS 6 4 5
Sex 0.218
Male 14 8 15
Female 5 9 7
Stage 0.068
IIIA 5 8 5
IIIB 3 4 2
IV 11 3 15
ECOG PS 0.013
0 1 4 2
1 17 8 10
2 1 5 10
OR, objective response; SD, stable disease; PD, progressive disease/cancer death;
NOS, not otherwise specified; ECOG PS, Eastern Cooperative Group performance
status. Patients with biopsy -proven stage III to IV non-small cell lung cancer not
suitable for curative surgery or radiotherapy were randomized to receive four cycles of
either DCb (docetaxel 75 mg/m2, carboplatin AUC 6) or MIC/MVP (mitomycin 6
mg/m2, ifosfamide 3 g/m2, cisplatin 50 mg/m2 or mitomycin 6 mg/m2, vinblastine 6
mg/m2, cisplatin 50 mg/m2, respectively), every 3 weeks.




Histology (n  66) 0.552
Squamous 15 (23) 14 (21)
Adenocarcinoma 6 (9) 11 (17)
Large cell 2 (3) 1 (2)
NSCLC- NOS 10 (15) 7 (11)
Sex (n  66) 0.428
Male 24 (36) 21 (32)
Female 9 (14) 12 (18)
Stage (n  64) 0.113
IIIA 11 (17) 8 (13)
IIIB 3 (5) 11 (17)
IV 17 (27) 14 (22)
ECOG PS (n  66) 0.687
0–1 24 (36) 26 (39)
2 9 (14) 7 (11)
Response (n  58) 0.794
ORR 12 (21) 7 (12)
SD 9 (160) 8 (14)
PD 12 (21) 10 (17)
OR, objective response; SD, stable disease; PD, progressive disease/cancer death;
NOS, not otherwise specified; ECOG PS, Eastern Cooperative Group performance
status.
a Data are presented as n(%).
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ingly, the presence of ERCC1 staining in the surgery plus
observation alone group was prognostic (adjusted hazard
ratio for death, 0.66; 95% CI: 0.49-0.90; p  0.009).24
Lord et al. reported the outcomes of 56 patients with
advanced NSCLC receiving gemcitabine/cisplatin chemo-
therapy according to ERCC1 mRNA expression derived from
paraffin-embedded pretreatment tumor samples. They noted
no significant association between expression and response
and a significantly longer median survival for patients with
low ERCC1 mRNA expression (61.6 weeks, 95%CI: 42.4–
80.7 weeks vs 20.4 weeks, 95%CI: 6.9–33.9 weeks, p 
0.046).23 Most recently, Ceppi et al. reported a significant
survival difference for 70 patients with advanced NSCLC
receiving gemcitabine/cisplatin chemotherapy who exhibited
low ERCC1 mRNA expression from archival samples (23.0
vs 12.4 months; p  0.0001).25
These studies seem to suggest that undetectable or low
ERCC1 expression, determined either by immunohistochem-
istry or real-time quantitative PCR, is a biomarker of im-
proved survival after platinum-based chemotherapy in
NSCLC. This may be somewhat surprising given the lack of
correlation between ERCC1 mRNA and protein levels pre-
viously reported.12,26 Our study failed to confirm a significant
association between ERCC1 mRNA expression, determined
by quantitative real-time PCR from archival samples, and
response to chemotherapy or survival in 66 patients with
advanced NSCLC treated with platinum-based chemotherapy
(DCb and MIC), but we acknowledge that this may reflect the
low power of the study implied by the wide confidence
intervals.
From the data to date, the observation of better out-
comes in chemotherapy-naive patients with higher ERCC1
expression is inconsistent with a predictive role for ERCC1
expression and chemotherapy response and suggests a bio-
logical effect unrelated to chemotherapy that requires expla-
nation. Considering the Kaplan-Meier overall survival plots
of ERCC1-positive and -negative tumors reported by Olaus-
sen et al.,24 patients followed by observation alone after
surgery and who had ERCC1-negative tumors attained a
median survival of approximately 3.8 years; this was im-
proved in the chemotherapy arm (approximately 4.8 years).
For patients with ERCC1-positive tumors, there was no
significant difference in survival between adjuvant chemo-
therapy and observation alone (median survival approxi-
mately 4.2 vs 4.8 years), a pattern consistent with ERCC1
absence identifying a more malignant phenotype, perhaps
with higher proliferation rates, such that patients without
chemotherapy may die more quickly as a consequence of
recurrent disease, a scenario often seen with highly malignant
tumors such as small cell lung cancer. If true, the benefits of
providing chemotherapy for less aggressive tumors would be
small and, in the Olaussen et al. study, could conceivably be
that of ERCC1-positive tumors. The report that ERCC1
expression levels are higher in tissues with higher prolifera-
tion rates27 would intuitively favor better outcomes for pa-
tients after chemotherapy, but this is at odds with the reported
mRNA expression studies discussed previously (with the
exception of ours) detailing better outcomes for low ERCC1
mRNA expression. We believe that the techniques we used,
specifically a confirmed non-differentially expressed NSCLC
control gene, and the technical correction that we applied21 to
compensate for the generally highly variable RT-PCR effi-
ciency characteristically associated with the amplification of
formalin-fixed paraffin-embedded biopsies have enabled us to
make very accurate assessments of ERCC1 expression. Thus,
we believe that technical factors may explain why our results
differ from those of others.
The potential existence of improved survival associated
with absent ERCC1 protein and high ERCC1 mRNA levels
most likely requires that the protein is rapidly degraded in
tumor cells. An example of such a phenomenon relates to
NADPH quinone oxidoreductase 1 and the presence of a
coding sequence polymorphism.28 Taken together with the
recent report of several polymorphisms of ERCC1 that alter
the activity of the protein, it is clear that additional laboratory
data are needed to determine the effect of ERCC1 polymor-
phisms on gene transcription and protein translation and their
effects on platinum cytotoxicity. Similarly, the recognition of
discordant ERCC1 mRNA expression between malignant and
non-malignant tissues from the same patient29 is concerning
in gene expression studies but is in conflict with advanced
NSCLC studies in which biopsies typically contains non-
malignant stromal tissue and the amount of available tissue
generally precludes extensive tissue processing.
An alternative explanation for the differences observed
in our study and those of Lord et al.23 and Ceppi et al.25 is the
heterogeneity of chemotherapy. Both previous studies used
platinum-gemcitabine chemotherapy, whereas we did not,
presuming that ERCC1 mRNA expression would be predic-
tive for all platinum-based chemotherapy. Despite similarly
sized studies, both Lord et al. and Ceppi et al. demonstrated
significant survival differences. Our study only had sufficient
FIGURE 2. Kaplan-Meier survival curve of patients with
non-small cell lung cancer according to median expression
of ERCC1. No significant difference in median survival was
demonstrated for patients receiving platinum-based chemo-
therapy (including docetaxel or mitomycin C/ifosfamide)
according to level of ERCC1 mRNA expression.
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power to detect a difference of 30% or greater in the propor-
tion surviving at a particular time point, which was clearly
only apparent for the two studies involving gemcitabine-
cisplatin, and may relate to the inhibition of DNA patch
synthesis by gemcitabine required for effective NER and that
seems to be the basis for the reported synergy between
gemcitabine and cisplatin.30
Given the complexities involved in handling mRNA
from archival sources and these conflicting results in ad-
vanced NSCLC, laboratory standards will need to be exacting
for any prospective trial using mRNA expression. In addition,
tissue availability is a particular problem in advanced NSCLC
and will likely remain a limiting factor in such studies. The
relationship of ERCC1 polymorphisms, mRNA, and protein
expression requires further consideration.
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